Challenges and advances of immune checkpoint therapy
Abstract Background and Objectives Immuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive bioma...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Clinical and Translational Discovery |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ctd2.70001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104979474350080 |
|---|---|
| author | Lingyu Li Yingli Sun |
| author_facet | Lingyu Li Yingli Sun |
| author_sort | Lingyu Li |
| collection | DOAJ |
| description | Abstract Background and Objectives Immuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive biomarkers are needed to enhance patient selection for the purpose of optimising effectiveness and reducing toxicity. This has driven efforts to decipher the immune and non‐immune factors that regulate ICT response. Main Content This review offers a thorough examination of the advantages and future challenges of immune checkpoint inhibitors in cancer therapy. Additionally, we explore ongoing efforts to address current challenges, such as guiding subsequent clinical trials, developing ICT combination therapy strategies and utilising epigenetics to enhance clinical efficacy. Conclusion and Perspectives Despite significant progress, ICT faces challenges including immune‐related adverse events (irAEs) and resistance mechanisms. Ongoing research focuses on developing novel biomarkers, combination therapies, and epigenetic strategies to improve the efficacy and safety of ICT for cancer patients worldwide. Future studies are required to validate these findings across different tumor types and treatment settings. |
| format | Article |
| id | doaj-art-6aae8a8cf4e043fcbf02f0288bd58da7 |
| institution | DOAJ |
| issn | 2768-0622 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Discovery |
| spelling | doaj-art-6aae8a8cf4e043fcbf02f0288bd58da72025-08-20T02:39:13ZengWileyClinical and Translational Discovery2768-06222024-12-0146n/an/a10.1002/ctd2.70001Challenges and advances of immune checkpoint therapyLingyu Li0Yingli Sun1Central Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College Shenzhen ChinaCentral Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College Shenzhen ChinaAbstract Background and Objectives Immuno‐checkpoint therapy (ICT) significantly alters the clinical course of cancer patients, providing long‐lasting clinical benefits and offering the potential for cure to some patients. However, response rates for different tumour types vary, and predictive biomarkers are needed to enhance patient selection for the purpose of optimising effectiveness and reducing toxicity. This has driven efforts to decipher the immune and non‐immune factors that regulate ICT response. Main Content This review offers a thorough examination of the advantages and future challenges of immune checkpoint inhibitors in cancer therapy. Additionally, we explore ongoing efforts to address current challenges, such as guiding subsequent clinical trials, developing ICT combination therapy strategies and utilising epigenetics to enhance clinical efficacy. Conclusion and Perspectives Despite significant progress, ICT faces challenges including immune‐related adverse events (irAEs) and resistance mechanisms. Ongoing research focuses on developing novel biomarkers, combination therapies, and epigenetic strategies to improve the efficacy and safety of ICT for cancer patients worldwide. Future studies are required to validate these findings across different tumor types and treatment settings.https://doi.org/10.1002/ctd2.70001biomarkersclinical trialsCTLA‐4immune checkpoint therapyPD‐1 |
| spellingShingle | Lingyu Li Yingli Sun Challenges and advances of immune checkpoint therapy Clinical and Translational Discovery biomarkers clinical trials CTLA‐4 immune checkpoint therapy PD‐1 |
| title | Challenges and advances of immune checkpoint therapy |
| title_full | Challenges and advances of immune checkpoint therapy |
| title_fullStr | Challenges and advances of immune checkpoint therapy |
| title_full_unstemmed | Challenges and advances of immune checkpoint therapy |
| title_short | Challenges and advances of immune checkpoint therapy |
| title_sort | challenges and advances of immune checkpoint therapy |
| topic | biomarkers clinical trials CTLA‐4 immune checkpoint therapy PD‐1 |
| url | https://doi.org/10.1002/ctd2.70001 |
| work_keys_str_mv | AT lingyuli challengesandadvancesofimmunecheckpointtherapy AT yinglisun challengesandadvancesofimmunecheckpointtherapy |